Drug Search Results
Using advanced filters...
Advanced Search [+]

Chymotrypsin

Alternative Names: chymotrypsin, alphachymotrypsin
Latest Update: 2025-02-04
Latest Update Note: News Article

Product Description

Mechanisms of Action: Protein Hydrolyzer

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Canada | Chile | Egypt | India | Ireland | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Spain | Switzerland | Taiwan | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Healthgen Biotechnology
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chymotrypsin

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acute Respiratory Distress Syndrome

Phase 1: Pleurisy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HY1005-2023-2-P1

P1

Not yet recruiting

Pleurisy

2025-07-01

HY1005-1-2024-P2

P2

Recruiting

Acute Respiratory Distress Syndrome

2025-04-30

Recent News Events